No Data
Tellgen Corporation (300642.SZ): A subsidiary obtained the registration certificate for fully automated chemiluminescence immunoassay medical instruments.
On March 3, Gelonghui reported that Tellgen Corporation (300642.SZ) announced that its wholly-owned subsidiary Jiangxi Tellgen Corporation Technology Co., Ltd. recently obtained a medical instruments registration certificate issued by the Jiangxi Provincial Pharmaceutical Supervision Administration. The product name is: Fully Automated Chemiluminescence Immunoassay Analyzer (Model and Specification: TESMIi200). The acquisition of this medical instruments registration certificate enriches the company's and Jiangxi Tellgen's instrument support in the chemiluminescence product line, which will further enhance the comprehensive competitiveness of the company and its subsidiaries in the field of in vitro diagnostics, favorable for further improving market expansion capabilities, and will have a positive impact on the company's future operation.
Tellgen Corporation (300642.SZ): Net income for the 2024 fiscal year is expected to decline by 54.14%-64.21%.
Gelonghui, on January 23, announced that Tellgen Corporation (300642.SZ) released its performance forecast for 2024. The net income attributable to shareholders of the listed company is expected to be between 32 million yuan and -41 million yuan, a decrease of 54.14% to 64.21% compared to the same period last year; excluding non-recurring gains and losses, the net income is expected to be between 24 million yuan and -31 million yuan, a decrease of 51.34% to 62.33% year-on-year. Due to market factors and the impact of the Industry central procurement, the company expects to achieve revenue of 0.4 billion yuan to -0.46 billion yuan in the reporting period, a year-on-year decline of 1.
Perspective Life: 2024 Annual Results Forecast
Tellgen Corporation (300642.SZ): Application for the change registration of medical instruments has been accepted.
On January 17, Gelonghui reported that Tellgen Corporation (300642.SZ) announced that the company recently received the "Acceptance Notification" issued by the National Medical Products Administration, accepting the company's application for a registration change of the "Human SHOX2 and RASSF1A gene methylation DNA detection kit (PCR fluorescence method)". The sample type for the company's Human SHOX2 and RASSF1A gene methylation DNA detection kit (PCR fluorescence method) is solely alveolar lavage fluid. Based on market and clinical usage needs, the company intends to apply to the National Medical Products Administration to expand the 'Human
Weak Statutory Earnings May Not Tell The Whole Story For Tellgen (SZSE:300642)
Perspective Life: Report for the third quarter of 2024
Need To Know: Analysts Just Made A Substantial Cut To Their Tellgen Corporation (SZSE:300642) Estimates
